184 related articles for article (PubMed ID: 37982711)
21. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
[TBL] [Abstract][Full Text] [Related]
22. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
Jandaghi P; Najafabadi HS; Bauer AS; Papadakis AI; Fassan M; Hall A; Monast A; von Knebel Doeberitz M; Neoptolemos JP; Costello E; Greenhalf W; Scarpa A; Sipos B; Auld D; Lathrop M; Park M; Büchler MW; Strobel O; Hackert T; Giese NA; Zogopoulos G; Sangwan V; Huang S; Riazalhosseini Y; Hoheisel JD
Gastroenterology; 2016 Dec; 151(6):1218-1231. PubMed ID: 27578530
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
24. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
[TBL] [Abstract][Full Text] [Related]
27. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
28. LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR-539.
Nai Y; Pan C; Hu X; Ma Y
Cancer Med; 2020 Jan; 9(2):757-767. PubMed ID: 31789465
[TBL] [Abstract][Full Text] [Related]
29. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA;
Cancer Res; 2021 Jul; 81(13):3461-3479. PubMed ID: 33980655
[TBL] [Abstract][Full Text] [Related]
30. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Zhang Y; Ma Y; Wang Y; Mukhopadhyay D; Bi Y; Ji B
Pancreatology; 2022 Jun; 22(5):619-625. PubMed ID: 35550115
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation.
Li L; Bao J; Wang H; Lei JH; Peng C; Zeng J; Hao W; Zhang X; Xu X; Yu C; Deng CX; Chen Q
Theranostics; 2021; 11(4):1672-1689. PubMed ID: 33408774
[No Abstract] [Full Text] [Related]
32. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
33. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
[TBL] [Abstract][Full Text] [Related]
34. A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells.
Li J; Ke J; Fang J; Chen JP
J Cell Biochem; 2020 Jan; 121(1):743-754. PubMed ID: 31478239
[TBL] [Abstract][Full Text] [Related]
35. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.
Harikumar KB; Kunnumakkara AB; Ochi N; Tong Z; Deorukhkar A; Sung B; Kelland L; Jamieson S; Sutherland R; Raynham T; Charles M; Bagherzadeh A; Foxton C; Boakes A; Farooq M; Maru D; Diagaradjane P; Matsuo Y; Sinnett-Smith J; Gelovani J; Krishnan S; Aggarwal BB; Rozengurt E; Ireson CR; Guha S
Mol Cancer Ther; 2010 May; 9(5):1136-46. PubMed ID: 20442301
[TBL] [Abstract][Full Text] [Related]
36. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
37. Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreatic Ductal Adenocarcinoma.
Carbone D; De Franco M; Pecoraro C; Bassani D; Pavan M; Cascioferro S; Parrino B; Cirrincione G; Dall'Acqua S; Sut S; Moro S; Gandin V; Diana P
Mar Drugs; 2023 May; 21(5):. PubMed ID: 37233482
[TBL] [Abstract][Full Text] [Related]
38. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
39. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
[TBL] [Abstract][Full Text] [Related]
40. KCNN4-mediated Ca
Mo X; Zhang CF; Xu P; Ding M; Ma ZJ; Sun Q; Liu Y; Bi HK; Guo X; Abdelatty A; Hu C; Xu HJ; Zhou GR; Jia YL; Xia HP
Acta Pharmacol Sin; 2022 Mar; 43(3):735-746. PubMed ID: 34183755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]